We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
-41.25%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$334M
AUM Growth
-$258M
Cap. Flow
-$2.78M
Cap. Flow %
-0.83%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.78M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$193M 57.63%
4,632,149
– –
FHTX icon
2
Foghorn Therapeutics
FHTX
$285M
$59.8M 17.9%
12,674,120
– –
SANA icon
3
Sana Biotechnology
SANA
$885M
$40.8M 12.19%
25,001,856
– –
OMGA
4
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$21.8M 6.52%
29,225,579
– –
MCRB icon
5
Seres Therapeutics
MCRB
$48.1M
$19.3M 5.76%
1,155,852
– –
SYRS
6
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-1,293,849
Closed -$2.78M

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q4 2024 Portfolio in Review

As of Q4 2024, Flagship Pioneering held 6 positions worth $334M, down 44% from $592M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering's Q4 2024 filing shows 1 closed position. The largest sale was Syros Pharmaceuticals, Inc. Common Stock, an estimated $2.78M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering fully exited Syros Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $2.78M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $334M portfolio in Q4 2024.
  • Flagship Pioneering opened 0 new positions and closed 1 in Q4 2024.
  • Flagship Pioneering's portfolio value fell 44% quarter-over-quarter to $334M.

Based on Flagship Pioneering's 13F filing for Q4 2024, filed 14 Feb 2025.